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The Ebola virus matrix protein VP40 plays an impor-
tant role in virion formation and viral egress from
cells. However, the host cell proteins and mecha-
nisms responsible for intracellular transport of VP40
prior to its contribution to virion formation remain to
be elucidated. Therefore we used coimmunoprecipi-
tation and mass spectrometric analyses to identify
host proteins interacting with VP40. We found that
Sec24C, a component of the host COPII vesicular
transport system, interacts specifically with VP40
via VP40 amino acids 303 to 307. Coimmunoprecipi-
tation and dominant-negative mutant studies indi-
cated that the COPII transport system plays a critical
role in VP40 intracellular transport to the plasma
membrane. Marburg virus VP40 was also shown to
use the COPII transport system for intracellular
transport. These findings identify a conserved
intersection between a host pathway and filovirus
replication, an intersection that can be targeted in
the development of new antiviral drugs.
INTRODUCTION
Ebola virus is an enveloped RNA virus of the family Filoviridae in
the order Mononegavirales. The virus causes severe hemor-
rhagic fever accompanied by extremely high mortality rates in
humans and nonhuman primates (Feldmann et al., 2003;
Sanchez et al., 2001). Effective vaccines and antiviral drugs
have not yet been licensed (Feldmann et al., 2003).
Ebola viral particles consist of seven structural proteins
encoded by a genome of nonsegmented, single-stranded, nega-
tive-sense RNA (Feldmann et al., 2003, 2004). Four viral
proteins—nucleoprotein (NP), viral protein 35 (VP35), VP30, and
L—and viral RNA form the nucleocapsid, which is responsible
for transcription and replication of the viral genome (Muhlberger
et al., 1999). Three other proteins—VP40, glycoprotein (GP), and168 Cell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier InVP24—are membrane-associated proteins. VP40 is the major ma-
trix protein, and its expression alone leads to the formation and
release of filamentous Ebola virus-like particles (VLPs) (Jasenosky
et al., 2001; Timmins et al., 2001). GP expression further enhances
the amount of VP40-induced VLP production (Licata et al., 2004).
A so-called late domain was originally identified in the retrovi-
rus gag protein as a region important for a late step in virus
budding (Gottlinger et al., 1991). This domain mediated interac-
tions with cellular proteins involved in multivesicular body sorting
machinery (Strack et al., 2000; VerPlank et al., 2001). Ebola virus
VP40 has two overlapping late domains (7-PTAP-10 and 10-
PPEY-13) that interact with Tsg101—a component of the endo-
somal sorting complex required for transport (ESCRT)-I—via its
PTAP motif and with the ubiquitin ligase Nedd4 via its PPXY motif
(Harty et al., 2000; Licata et al., 2003; Yasuda et al., 2003). These
host proteins play a role in the last step of virus budding (Hartlieb
and Weissenhorn, 2006; Martin-Serrano et al., 2001). The effi-
ciency of Ebola VLP production is reduced by alteration of the
late domains of VP40 by amino acid substitutions or by inhibition
of Nedd4 function (Harty et al., 2000; Yasuda et al., 2003).
However, the interaction between VP40 late domains and these
cellular proteins are not essential for Ebola viral replication, since
a mutant Ebola virus possessing substitutions abolishing both of
the VP40 late domains was able to replicate with only a one log
unit reduction in virus titers in cell culture (Neumann et al., 2005).
VP40 has to be transported to the plasma membrane before it
induces VP40-mediated VLP production at the plasma mem-
brane (Noda et al., 2002; Panchal et al., 2003). Thus, we chose
a proteomics approach to identify cellular machineries responsi-
ble for the intracellular transport of VP40. Here we demonstrate
that the COPII transport system is responsible for the intracellu-
lar transport of Ebola virus VP40.
RESULTS
ATandem-Tag-Based Pull-DownAnalysis Reveals Ebola
Virus VP40 Interaction with Sec24C
To identify the host factors responsible for intracellular transport
of Ebola virus VP40, we employed a tandem-tag-basedc.
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VP40 Trafficking and COPII TransportFigure 1. Interaction between VP40 and Sec24C
(A) Identification of host proteins interacting with VP40. 293T cells were
transfected with a plasmid expressing either FLAG and HA-tagged
VP40 (FH-VP40) or authentic VP40. The cell lysates were subjected to
immunoprecipitation with anti-FLAG and anti-HA antibodies, sequentially.
Coimmunoprecipitated host proteins were resolved by SDS-PAGE. The
band marked by an asterisk represents FH-VP40, while the arrowheads
indicate the proteins analyzed by the MALDI-TOF-TOF/MS system.
(B) Schematic diagram of the vesicle budding process of the COPII
complex. Activation of Sar1 by a guanine nucleotide exchange factor
(GEF) (step I) leads to membrane recruitment and formation of a Sec23/
24 complex (step II), cargo selection, and coat polymerization by Sec13/
31 complex (step III). This figure was modified from Bickford et al. (2004).
(C) VP40 immunoprecipitates endogenous Sec24C and Sec23. A plasmid
encoding either FLAG-tagged wild-type VP40 or an empty vector was
transfected into 293 cells. The cell lysates were subjected to immunopre-
cipitation with an anti-FLAG or an anti-Sec24C antibody. The precipitated
proteins were analyzed by western blot analysis with an anti-VP40,
-Sec24C, -Sec23, or -FLAG antibody. Input and IP denote the total cell
lysates and immunoprecipitated samples, respectively.
(D) VP40 interacts with Sec24C during Ebola virus infection. Three days
after infection of Zaire Ebola virus, cell lysates were subjected to immuno-
precipitation with an anti-VP40 antibody. The precipitated proteins were
analyzed by western blot analysis using an anti-Sec24C, -VP40, -VP24,
-GP, or -NP antibody.pull-down assay. For this purpose, we constructed a plasmid
expressing VP40 with both a FLAG and an HA tag at its N termi-
nus (FH-VP40) and examined the properties of this mutant,
including its expression level, reactivity with a panel of monoclo-
nal antibodies, intracellular distribution, VLP formation (Figure S1
available online), and the shapes of the VLPs induced by the
tandem-tagged VP40. There were no appreciable differences
between FH-VP40 and authentic VP40 except for the reactivity
of the tandem-tagged VP40 with anti-FLAG and anti-HA
antibodies and the apparent molecular weight due to the tags
(data not shown). Next, we applied FH-VP40 to a tandem-tag-
based pull-down assay for identification of host proteins inter-
acting with VP40, leading to the identification of ten host proteins
that interact with VP40: LARP (Gene ID 23369), DHX9 (1660),
HNRPU (3192), Sec24C (9632), NCL (4691), ILF3 (3609),
DDX21 (9188), HSPA9B (3313), HSPA5 (3309), and HSPA8
(3312) (Figure 1A).
Among these proteins, we selected Sec24C for further study
because it is a component of the COPII complex, which is
responsible for ER-to-Golgi transport of vesicles (Bickford
et al., 2004; Haucke, 2003; Watson and Stephens, 2005) and is
possibly involved in VP40 intracellular transport. Formation of
the COPII complex requires assembly of the coat proteins
Sec23/Sec24, Sec13/Sec31, and Sar1 (Barlowe, 2002), a pro-
cess initiated by GDP-to-GTP exchange on GTPase Sar1, which
belongs to an ADP ribosylation factor (ARF) family (Figure 1B,
step I). Activated Sar1 recruits a heterodimeric complex of
Sec23/Sec24 to generate a prebudding complex (Figure 1B,
step II). Finally, recruitment of Sec13/Sec31 heterodimers
induces ER membrane deformation and budding of vesicles
coated with COPII complex (Figure 1B, step III). During vesicle
formation, cargo proteins are selected and concentrated by
Sec24 (Kuehn et al., 1998). The Sec24 family has four members,
Sec24A, Sec24B, Sec24C, and Sec24D (Pagano et al., 1999),
and Sec24C has been shown to interact with Sec23A by yeast
two-hybrid assays (Pagano et al., 1999).CSince Sec24C exists as a heterodimeric complex with
Sec23 in cells (Barlowe, 2002), we analyzed whether VP40
precipitated not only Sec24C but also Sec23. We found that
both proteins were immunoprecipitated with VP40 (see IP:
anti-FLAG in Figure 1C). Moreover, when a rabbit antibody
against Sec24C was used to immunoprecipitate endogenous
Sec24C from cell lysates, VP40 was coimmunoprecipitated
(see IP: anti-Sec24 panel in Figure 1C). To further confirm
that VP40 specifically interacts with Sec24C, we performed
immunoprecipitation/western blot assays by coexpressing
cMyc-tagged Sec24C (cMyc-Sec24C) and authentic VP40,
FLAG-tagged VP40 (FLAG-VP40), or FLAG-tagged enhanced
green fluorescent protein (FLAG-GFP; negative control).
FLAG-VP40 was also coexpressed with a cMyc-tagged VP40
as a positive control for this assay, since VP40 forms
a homo-oligomer (Panchal et al., 2003). As shown in Figure S2,
both cMyc-Sec24C (lane 7) and cMyc-VP40 (lane 12) were
coimmunoprecipitated using an anti-FLAG antibody. However,
with an anti-FLAG antibody, cMyc-Sec24C did not coimmuno-
precipitate with FLAG-GFP (lane 11). The results suggest the
specific interaction of cMyc-Sec24C and cMyc-VP40 with
FLAG-VP40. The same observation was made in reverse
experiments (i.e., coimmunoprecipitation of FLAG-VP40 with
cMyc-Sec24C with use of an anti-cMyc antibody and detec-
tion of coimmunoprecipitated VP40 with use of an anti-FLAG
antibody, data not shown). These results indicate that
VP40 specifically interacts with endogenous and exogenous
Sec24C.
Next, we attempted to demonstrate an interaction between
VP40 and Sec24C during Ebola virus infection. To this end, we
infected 293 cells with authentic Ebola virus, prepared lysates
from Ebola virus-infected cells, and performed immunoprecipi-
tation assays with an anti-VP40 antibody. We found that
endogenous Sec24C was coimmunoprecipitated with VP40
(Figure 1D). These data indicate that VP40 interacts with
Sec24C during Ebola virus infection.ell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier Inc. 169
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and FLAG-Sec23A Shifted to the Plasma Membrane
upon Coexpression of cMyc-VP40
To visually examine VP40 interaction with Sec23A/Sec24C
heterodimer, we evaluated the intracellular localization of both
Sec23A and Sec24C in the presence (Figure 2B) or absence
(Figure 2A) of VP40. In 293 cells expressing both Sec23A and
Sec24C, Sec23A colocalized with Sec24C as punctuated stain-
ing in the perinuclear region (Figure 2A). The intracellular localiza-
tion of both proteins shifted to the plasma membrane (Figure 2B,
arrows) upon expression of VP40, and both proteins colocalized
there with VP40.
Ebola VLP Production Is Reduced by Downregulation
of Endogenous Sec24C or Sar1
To evaluate the direct contributions of endogenous Sec24C and
Sar1 to Ebola VLP release, we applied RNA interference for
specific knockdown of mRNA encoding Sec24C or Sar1. Murine
leukemia virus (MuLV) possessing the shRNA cassette for GFP
(control), Sec24C, or Sar1 and pseudotyped with vesicular sto-
matitis virus-glycoprotein (VSV-G) was inoculated into 293 cells,
and the cells were then maintained with puromycin (1 mg/ml) for
selection of MuLV-infected cells. shRNA-expressing cells,
designated shGFP 293, shSec24C 293, and shSar1 293, were
used without further cloning.
To confirm whether the expression levels of target proteins
were reduced in these shRNA-expressing cells, cell lysates
Figure 2. VP40 Colocalizes with Sec24C and Sec23A at the Plasma
Membrane
FLAG-Sec23A and cMyc-Sec24C were expressed in the presence (B) or
absence (A) of VP40. After 24 hr, the cells were fixed and stained with a
combination of an anti-FLAG, an anti-cMyc, or an anti-VP40 antibody. Arrows
indicate accumulation of VP40, cMyc-Sec24C, and/or FLAG-Sec23A.170 Cell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier Inwere prepared and analyzed by western blot analysis using an
anti-Sec24C antibody, an anti-Sar1 antibody, or an anti-b-actin
antibody (Figure 3A). The results showed that the expression
levels of Sec24C in shSec24C 293 cells and Sar1 in shSar1
293 cells were reduced as compared with those in shGFP 293
cells. To further demonstrate the reduction of expression levels
of Sec24C and Sar1 in the shRNA-expressing cells, we per-
formed functional analyses by transfecting these cells with
a plasmid expressing secreted alkaline phosphatase (SEAP)
and examining the amount of SEAP secreted in the culture
supernatants (Figure 3B). The results showed that the secretion
index (calculated as described in the legend of Figure 3B) of
shSec24C 293 cells or of shSar1 293 cells was reduced to
68.6% or 68.2%, respectively, as compared with that of shGFP
293 cells (p < 0.001 by Student’s t test).
We subsequently used these cells to compare the efficiency of
VLP production by measuring the amounts of VLPs by western
blot analysis with an anti-VP40 antibody (Figure 3C). In cell
lysates, VP40 was detected at a similar level among all test
samples. Although the efficiency of VLP production was not
appreciably reduced (93%) in shGFP 293 cells, it was lowered
to 38% in shSec24C 293 cells and to 42% in shSar1 293 cells.
These results indicate that the COPII transport system involving
Sar1 and Sec24C is required for efficient VLP production.
Figure 3. VP40-Mediated VLP Production Is Reduced by Downregu-
lation of Endogenous Sec24C or Sar1
(A) Protein expression levels of Sec24C and Sar1. Cell lysates were prepared
from normal 293, shGFP 293, shSec24C 293, or shSar1 293 cells, and
analyzed by western blot analysis using an anti-Sec24C, an anti-Sar1, or an
anti-b-actin antibody.
(B) Reduction of SEAP secretion in shSec24C 293 or shSar1 293 cells. shGFP
293, shSec24C 293, and shSar1 293 cells were transfected with a plasmid
expressing SEAP and SEAP activity in the supernatants and within these cells
were measured. The data are presented as a secretion index, defined as the
ratio of SEAP activity detected in the culture supernatant to the intracellular
SEAP activity (n = 3). p values were determined by Student’s t test.
(C) Reduction of VLP release from shSec24C 293 or shSar1 293 cells. A
plasmid encoding authentic VP40 was transfected into normal 293, shGFP
293, shSec24C 293, or shSar1 293 cells. Released VLPs and total cell lysates
were analyzed by western blot analysis with an anti-VP40 antibody. The inten-
sities of the VP40 bands were quantified. The extent of VLPs in the first lane
from the left was set to 100%. The results shown are representative of three
independent experiments.c.
Cell Host & Microbe
VP40 Trafficking and COPII TransportDominant-Negative Mutants of Sar1 Inhibit VLP
Production by Interfering with the Plasma Membrane
Accumulation of VP40
To evaluate the functional contributions of the COPII transport
system to VLP release, we used two dominant-negative mutants
of Sar1, Sar1_T39N and Sar1_H79G, which are well character-
ized as COPII transport inhibitors (Ward et al., 2001). To confirm
the inhibitory effect of these mutants, we examined the expres-
sion of VSV-G protein on the cell surface (Figure 4A). Although
the cell surface expression of VSV-G was not appreciably
affected by coexpression with Sar1, it was decreased to
37.2% upon coexpression with Sar1_T39N, and to 6.1% with
Sar1_H79G. Similar levels of inhibition by these dominant-nega-
tive mutants of Sar1 were observed for the secretion of SEAP
(Figure S3). We then evaluated their effects on VP40-induced
VLP production by measuring the amount of VP40 released
into culture supernatant by western blot analysis with an
Figure 4. Dominant-Negative Mutants of Sar1 Interfere with VLP
Production by Inhibition of VP40 Plasma Membrane Accumulation
(A) VSV-G transport to the cell surface was inhibited by dominant-negative
mutants of Sar1. VSV-G was coexpressed with an indicated protein in 293T
cells. VSV-G on the cell surface was analyzed by flow cytometry using an
anti-VSV-G antibody. Red lines indicate the results with a goat anti-VSV-G
antibody, and black lines indicate the results with a normal goat antibody as
a primary antibody.
(B) Dominant-negative mutants of Sar1 inhibit VP40-induced VLP production.
VP40 was expressed in the absence (first lane from the left) or presence of
FLAG-Sar1 (second lane from the left), FLAG-Sar1_T39N (third lane from the
left), or FLAG-Sar1_H79G (fourth lane from the left) in 293T cells. Released
VLP and total cell lysates were analyzed by western blot analysis with an
anti-FLAG or an anti-VP40 antibody. The intensities of the VP40 bands were
quantified; the amount of VP40 in the first lane from the left was set to
100%. The results shown are representative of three independent experi-
ments.
(C) Dominant-negative mutants of Sar1 interfere with the accumulation of
Venus-VP40 at the plasma membrane. Venus-VP40 was expressed in the
presence or absence of FLAG-Sar1, FLAG-Sar1_T39N, or FLAG-Sar1_H79G
in living 293T cells. The cells were stained with ER-tracker Blue-White and
visualized with a confocal microscope. Venus-VP40 was detected as bright
yellow, and ER was detected as light blue.Canti-VP40 and an anti-FLAG antibody (Figure 4B). In cell lysates,
VP40 and FLAG-Sar1 or its dominant-negative mutants were
detected at similar levels. Although the efficiency of VLP produc-
tion as measured by the amount of VP40 released into culture
supernatants was not appreciably influenced by coexpression
with Sar1 (second lane from the left), it was decreased to 61%
upon coexpression with Sar1_T39N (third lane from the left),
and to 12% with Sar1_H79G (fourth lane from the left). These
results indicate that the COPII transport system, especially
when involved in formation of the prebudding complex by
Sar1, is required for efficient VLP production.
To determine the steps at which Sar1 dominant-negative
mutants inhibit Ebola VLP production, we assessed the intracel-
lular localization of VP40 in living cells in their presence. To
visualize VP40 in living cells, we fused VP40 at the N terminus
to Venus (Venus-VP40), a derivative of enhanced yellow fluores-
cent protein (EYFP) that was optimized for expression in
mammalian cells. Venus-VP40 induced VLP production as effi-
ciently as the wild-type VP40 and other VP40s with a short tag
(Figure S1). Next, Venus-VP40 was expressed in the presence
or absence of FLAG-Sar1, FLAG-Sar1_T39N, or FLAG-
Sar1_H79G in 293T cells. Twenty-four hours posttransfection,
cells were stained with ER-tracker Blue-White and examined
by confocal microscopy (Figure 4C). Venus-VP40 was mainly
associated with the plasma membrane with limited signals in
the cytoplasm (top, empty vector). This plasma membrane
association of Venus-VP40 was not appreciably altered by coex-
pression with FLAG-Sar1 (top, FLAG-Sar1). By contrast, the
intracellular localization of Venus-VP40 was altered in the pres-
ence of dominant-negative mutants (top, FLAG-Sar1_T39N
and FLAG-Sar1_H79G); it was mainly detected in the cytoplasm,
and its association with the plasma membrane was substantially
diminished. In addition, VP40 did not colocalize with an ER
marker in the presence or absence of the dominant-negative
mutants (Figure 4C Bottom) or with a Golgi marker (Figure S4).
Similar results were obtained by using 293 cells and Cos-7 cells
(data not shown). These results indicate that the dominant-
negative mutants of Sar1 interfere with VP40-induced VLP
production by inhibiting the accumulation of VP40 at the plasma
membrane.
VP40 Amino Acid Residues Essential for Its Interaction
with Sec24C Are required for Its Accumulation
at the Plasma Membrane
To map the regions of VP40 important for its interaction with
Sec24C, we generated a series of VP40 deletion mutants with
FLAG tag at their N terminus (Figure 5A). To examine their inter-
action with Sec24C, we coexpressed Sec24C with these
deletion mutants and immunoprecipitated with an anti-FLAG
antibody, followed by Western blot analysis with an anti-
Sec24C antibody, or by Coomassie brilliant blue (CBB) staining
(Figure 5B). The expression levels of VP40 deletion mutants
and Sec24C were confirmed by western blot analysis with
an anti-FLAG and an anti-Sec24C antibody, respectively
(Figure 5B, Input). The results showed that VP40 mutants lacking
N-terminal regions still bind to Sec24C (Figure 5B, IP, anti-
Sec24C), although the amount of Sec24C in these samples
were higher than that in the wild-type VP40 sample (Figure 5B,
Input, anti-Sec24C). Even though the expression levels ofell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier Inc. 171
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VP40 Trafficking and COPII TransportFigure 5. Identification of the VP40 Region Interacting with Sec24C
(A) Schematic diagrams of VP40 deletion mutants. A series of VP40 deletion
mutants was constructed by sequential deletion from the N or C terminus of
VP40. A FLAG tag was added at the N terminus of the open reading frame.
(B) Sec24C coprecipitated with N-terminal deletion mutants, but not with
C-terminal deletion mutants. Each plasmid described in Figure 5A was
cotransfected with a plasmid encoding an authentic Sec24C into 293T cells.
The cell lysates were subjected to coimmunoprecipitation with an anti-FLAG
antibody. The precipitated proteins were analyzed by western blot analysis
with an anti-Sec24C antibody or by CBB stain. Input and IP denote the total
cell lysates and immunoprecipitated samples, respectively. Asterisks indicate
the bands of wild-type or mutant VP40s. The results shown are representative
of four independent experiments.FLAG-VP40DN80 and FLAG-VP40DN120 were low, they still
coprecipitated Sec24C. By contrast, three C-terminal deletion
mutants of VP40 failed to coprecipitate Sec24C. These data
suggest that the region spanning amino acids at position
287–326 of VP40 is important for its interaction with Sec24C.
To further refine the Sec24C interaction domain in VP40, we
prepared a series of plasmids expressing FLAG-tagged VP40
with multiple alanine substitutions (Figure 6A). Expression of
these mutants was confirmed by western blot analysis with an
anti-FLAG antibody and an anti-VP40 polyclonal antibody (data
not shown). These FLAG-tagged alanine-scanning VP40
mutants were used to evaluate their ability to coimmunoprecipi-
tate Sec24C. Under conditions in which similar levels of Sec24C
and VP40 mutants were expressed (Figure 6B, the panels indi-
cated by Input), and similar amounts of VP40 mutants were
immunoprecipitated with an anti-FLAG antibody (Figure 6B,
the panels indicated by IP, anti-VP40), FLAG-VP40_303-306A
and FLAG-VP40_305-308A did not coimmunoprecipitate
Sec24C as efficiently as the wild-type protein and other VP40
mutant proteins (Figure 6B, the panels indicated by IP,
anti-Sec24C).
We next examined the ability of these VP40 mutants to induce
VLP production as an indicator of plasma membrane accumula-
tion, since VP40 accumulation at the plasma membrane was
associated with efficient VLP production (see Figure 4). Although
all VP40 mutants were expressed at an equivalent level
(Figure 6C, upper panel), VLP production was substantially
reduced with FLAG-VP40_286-288A, FLAG-VP40_289-291A,
FLAG-VP40_303-306A, and FLAG-VP40_305-308A. In addition,172 Cell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier IncVLP production was appreciably reduced with FLAG-
VP40_314-316A. These data suggest that the region spanning
amino acids at position 303–308 of VP40 is important for its inter-
action with Sec24C and thus VP40-induced VLP production and
that the regions at amino acids 286–291 and at amino acids
314–316 of VP40 are important for VP40-induced VLP release
but not for interaction with Sec24C. These mutant VP40s, which
are deficient in VLP production but interact normally with
Sec24C, failed to accumulate at the plasma membrane (data
not shown).
To identify the individual amino acids essential for interaction
with Sec24C, we prepared a second series of plasmids express-
ing VP40 with a single alanine substitution (Figure 7A). Again,
under the conditions in which similar levels of Sec24C and
Figure 6. The Region at Amino Acids 303 to 308 of VP40 Is Important
for Both Interaction with Sec24C and VLP Production
(A) Schematic diagrams of multi-alanine-scanning mutants of VP40. A series of
such mutants was constructed by the substitution of amino acids for alanine
from 286 to 326, sequentially. A FLAG tag was added at the N terminus of
the open reading frame.
(B) Comparison of the interaction of multi-alanine-scanning mutants of VP40
with Sec24C. The immunoprecipitation assay/western blot analysis was
performed as described in Figure 5 with an anti-FLAG antibody for IP assay
and either an anti-Sec24C or an anti-VP40 antibody for sestern blot analysis,
respectively. Input and IP denote the total cell lysates and immunoprecipitated
samples, respectively. The results are representative of three independent
experiments.
(C) Comparison of the efficiency of VLP production among multi-alanine
mutants. A VLP release assay was performed as described in Figure 4 with
293T cells. The results are representative of three independent experiments..
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by Input), the amount of coprecipitated Sec24C, normalized to
the amount of its VP40 immunoprecipitated with an anti-FLAG
antibody (Figure 7B, the panels indicated by IP, anti-VP40),
was reduced to 46% for FLAG-VP40_L303A, to 56% for FLAG-
VP40_V306A, and to 64% for FLAG-VP40_I307A (Figure 7B,
the panels indicated by IP, anti-Sec24C). Interestingly, the
amount of Sec24C coimmunoprecipitated with FLAG-
VP40_M305A was increased to 186%. These data indicate that
amino acids at position 303L, 305M, 306V, and 307I of VP40
are involved in the interaction with Sec24C.
We next determined the cellular localization of Sec24C inter-
action-deficient VP40 mutants (Figure 7C). Unlike a FLAG-
tagged wild-type VP40 that was clearly associated with the
plasma membrane, as described above (Figure 2B), the plasma
membrane association was unclear, with VP40 mutants having
a reduced level of Sec24C interaction (i.e., FLAG-VP40_L303A,
FLAG-VP40_V306A, and FLAG-VP40_I307A). However, FLAG-
VP40_T304A and FLAG-VP40_T308A, which showed properties
similar to wild-type VP40 for Sec24C interaction and VLP pro-
duction, were associated with the plasma membrane as was
shown with wild-type VP40. FLAG-VP40_M305A, which showed
an enhanced interaction with Sec24C, but reduced VLP produc-
tion, associated with the plasma membrane, but bleb-like struc-
tures containing the mutant VP40 were apparent on the cell
surface. To examine the nature of this unique structure, we
undertook scanning electron microscopic (SEM) analysis of the
Figure 7. 303L, 305M, 306V, and 307I of VP40 Are Essential for
Both the Interaction with Sec24C and Its Accumulation at the
Plasma Membrane
(A) Schematic diagrams of single alanine-scanning mutants of VP40. A
series of such mutants of VP40 was constructed by substitution of each
amino acid to alanine from 303 to 308, sequentially. A FLAG tag was
added at the N terminus of the open reading frame.
(B) Comparison of interaction of VP40 single alanine mutants with
Sec24C. The immunoprecipitation assay/western blot analysis was
performed as described in Figure 6. Input and IP denote the total cell
lysates and immunoprecipitated samples, respectively. The intensities
of the Sec24C and VP40 bands were quantified. The extent of Sec24C
was normalized to the extent of its VP40 level, and the value in the first
lane from the left was set to 100%. The results shown are representative
of three independent experiments.
(C) FLAG-VP40_L303A, FLAG-VP40_V306A, and FLAG-VP40_I307A
failed to accumulate at the plasma membrane. Immunofluorescence
assay was performed as described in Figure 2 with an anti-VP40 antibody
(red). The nuclei were stained with DAPI (blue).
(D) FLAG-VP40_M305A induces lumps on the cell surface. 293 cells trans-
fected with either an expression plasmid with no insert (empty vector) or
a plasmid encoding either FLAG-VP40 or FLAG-VP40_M305A were
analyzed by SEM as described in the Experimental Procedures. Inset
shows a higher magnification of a portion of the cells. The edges of cells
transfected with an empty vector were traced with a white line (left panel).
Arrowheads and arrows indicate filamentous VLPs induced by wild-type
or lumps induced by FLAG-VP40_M305A, respectively.
cells expressing FLAG-VP40_M305A (Figure 7D). Many
filamentous VLPs were protruding from the exterior of the
cells expressing wild-type VP40 (Figure 7D, arrowheads),
while none were observed on cells transfected with an empty
plasmid. These filamentous VLPs were indistinguishable
from those observed in cells infected with authentic Ebola virus,
as reported previously (Watanabe et al., 2004). Many lumps were
apparent at the surface of cells expressing VP40_M305A, which
had a higher binding activity with Sec24C (Figure 7C, upper right
panel; Figure 7D, right panel).
We next examined the efficiency of VLP production with these
point mutants by measuring the amount of VP40 detected in the
culture supernatant and transmission electron microscopy. The
results showed that, with the exception of VP40_M305A mutant,
the extent of VLP production was correlated with their interac-
tion with Sec24C (i.e., less Sec24C association corresponded
to less VLP production) (Figure S5). In cells expressing
VP40_I307A, we never found VLP budding, although the trans-
fection efficiency of these cells with plasmids was more than
50%, based on an immunofluorescent assay examining over
100 cells (Figure S5B and data not shown), while in cells
expressing other mutants or wild-type, VLP budding was readily
observed (Figure S5B). Although VP40_M305A mutant inter-
acted more efficiently with Sec24C than with wild-type VP40,
VLP production was reduced with this mutant. These data
suggest that balanced interplay between VP40 and Sec24C is
essential for the accumulation of VP40 at the plasma membrane
and for VLP release.
To eliminate the possibility that VP40 expression from a plas-
mid affects the secretory pathway in general by tying up the
Sec24C, we examined the level of SEAP in the culture superna-
tant by coexpressing FLAG-VP40 or FLAG-GFP (Figure S6).Cell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier Inc. 173
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SEAP secretion into the culture supernatant, suggesting the
lack of any general effect of VP40 expression on the secretory
pathway.
Do Other Viral Matrix Proteins Use the COPII Transport
System for Their Intracellular Transport?
Since the COPII transport system was used for intracellular
transport of Ebola virus VP40, we next examined whether it
also functions with other viral matrix proteins that induce VLP
production. To this end, we expressed human immunodefi-
ciency virus-1 (HIV-1) gag (Strack et al., 2000), Lassa virus Z
(Perez et al., 2003), and Marburg virus VP40 (Kolesnikova
et al., 2004) in the presence or absence of FLAG-Sar1 or its dom-
inant-negative mutants. The released VLPs were collected, and
the efficiency of VLP production was examined by western blot
analysis. Coexpression of FLAG-Sar1 or dominant-negative
mutants of Sar1 did not affect VLP production induced by HIV-
1 gag or Lassa virus Z (data not shown). By contrast, the VLP
production induced by Marburg VP40 was inhibited by coex-
pression with dominant-negative mutants of Sar1; the efficiency
of VLP production was reduced to 59% with Sar1_T39N and to
32% with Sar1_H79G (Figure S7A).
To characterize the inhibitory effects of Sar1 dominant-nega-
tive mutants on Marburg VP40-induced VLP production, Mar-
burg VP40 was expressed in presence or absence of Sar1
dominant-negative mutants in 293 cells. Marburg VP40 accu-
mulated to the multivesicular bodies (MVB), the budding site
of Marburg virus (Figure S7B, arrows), as reported previously
(Kolesnikova et al., 2004). Coexpression of the wild-type Sar1
did not alter Marburg VP40 localization (+FLAG-Sar1 in
Figure S7B, arrows), while coexpression of Sar1 dominant-neg-
ative mutants reduced Marburg VP40 accumulation to the MVB
(+FLAG-Sar1_T39N and +FLAG-Sar1_H79G in Figure S7B,
arrowheads). Since these data indicate that intracellular trans-
port of Marburg VP40 to the viral budding site depends on
the COPII transport system, we evaluated the interaction of
Marburg VP40 with Sec24C biochemically and microscopically.
Marburg VP40 (Figure S7C) was not coprecipitated with
Sec24C under conditions in which Ebola VP40 was
efficiently precipitated, and did not colocalize with Sec24C
(Figure S7D). Similarly, HIV-1 gag or Lassa Z was not copreci-
pitated with Sec24C (Figure S8A).
We then compared the efficiency of VLP production in the
shGFP, shSec24C, or shSar1 293 cells. Although the efficiency
of VLP production was not appreciably reduced (93%) in
shSec24C 293 cells, it was reduced to 57% in shSar1 293 cells
(Figure S7E). By contrast, the knockdown of Sec24C or Sar1 did
not appreciably reduce VLP production induced by HIV-gag or
Lassa Z protein (Figure S8B).
These results indicate that Marburg VP40 uses the COPII
transport system for its intracellular transport, but the specific
interacting cellular protein appears to be different from that of
Ebola VP40 (i.e., Sec24C). The results also show that this trans-
port system is not involved in VLP production mediated by HIV-1
gag and Lassa Z proteins and that the inhibition of the secretory
pathway by the knockdown of Sec24C or Sar1 does not have
nonspecific, general inhibitory effects on the egress of envel-
oped viruses.174 Cell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier InDISCUSSION
Here we show that Sec24C plays a critical role in the intracellular
transport of Ebola VP40 to the plasma membrane. Amino acid
substitutions in VP40 that abolished interaction with Sec24C
and dominant-negative mutants of Sar1 that inhibited the COPII
transport system interfered with the ability of VP40 to accumu-
late at the plasma membrane, suggesting that VP40 utilizes the
COPII transport system though interaction with Sec24C during
intracellular transport to the plasma membrane, an essential
step for viral egress by VP40-mediated virion formation. Marburg
VP40, but not HIV-1 and Lassa virus matrix proteins, also appear
to use the COPII transport system for this purpose. Since the
COPII transport system works at an initial step of secretory
pathway in ER-Golgi transport under normal conditions, VP40
may encounter Sec24C at an early point of its intracellular trans-
port, but the manner in which it is transported to the plasma
membrane remains unclear. Since the intracellular locations of
Sec24C and Sec23A shift to the plasma membrane upon coex-
pression with VP40, it is possible that transport of VP40 to the
plasma membrane may be mediated by the COPII transport
system. An example of such an altered intracellular localization
of cellular proteins is Tsg101, which normally exists in late endo-
some, but is recruited to the plasma membrane upon expression
with Ebola VP40 (Panchal et al., 2003). Alternatively, the COPII
transport system may play an initial role in the intracellular trans-
port of VP40, followed by a role in other trafficking pathways
(such as the COPI transport system [Bethune et al., 2006]),
through which VP40 is eventually transported to the plasma
membrane. Thus, it will be important to study other host
proteins/machineries that might contribute to VP40 intracellular
transport.
Ebola VP40 interacts with Sec24C via amino acids 303–307
(303-LTMVI-307), which are conserved among all reported Ebola
virus species and strains: Zaire Ebola virus, strain Mayinga
(accession number AAD14583) and strain Gabon (accession
number Q2PDK5); Sudan Ebola virus, strain Uganda (accession
number Q5XX06) and strain Gulu (accession number YP138522);
Reston Ebola virus, strain Reston (accession number Q91DD9)
and strain Pennsylvania (accession number AAN04450). The
crystal structure of VP40 (Dessen et al., 2000) indicates that
this region is exposed on its surface and is folded into a b strand
with amino acids extending to position 310, supporting the
possibility that the VP40 molecule interacts with Sec24C via
these amino acids. Interestingly, amino acids at positions 303–
307 are not conserved between Ebola and Marburg VP40s.
Although both Ebola and Marburg VP40s use the COPII transport
system for their intracellular transport to the budding site, the
former (Figures 1C and 1D), but not the latter (Figure S7C), inter-
acts with Sec24C. Since the Sec24 family has four members,
Sec24A, Sec24B, Sec24C, and Sec24D, Marburg VP40 may
interact with Sec24 family members other than Sec24C during
its intracellular transport. The cocrystallization of Ebola VP40
with Sec24C should reveal Sec24 interaction with these matrix
proteins at the atomic level. The Sec24C domains responsible
for interaction with cargos are not fully defined. In general,
Sec24 recognizes specific motifs in the cytoplasmic tails of
transmembrane proteins, such as the di-acidic motif first
discovered in VSV-G (Nishimura and Balch, 1997) and thec.
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1997) and p24 proteins (Fiedler et al., 1996), via its cargo-binding
domains (Bickford et al., 2004). Since the interaction region on
VP40 differs from these motifs, and VP40 is not a transmembrane
protein, VP40 might interact with Sec24C via a novel site on
Sec24C.
Because the transport of COPII-coated vesicles from the ER to
the Golgi is microtubule dependent (Presley et al., 1997), COPII-
coated vesicles must be coupled to microtubules and motor
proteins recruited as the driving forces. In fact, the COPII com-
plex directly binds to dynactin (a component of a motor protein
dynien associated with microtubules) via the p150Glued subunit
(Watson et al., 2005), and COPII transport is inhibited by treat-
ment with nocodazole (Presley et al., 1997), which causes micro-
tubule depolymerization. In accord with these findings, we have
shown that VP40-induced VLP production is also inhibited by
microtubule disruption due to nocodazole treatment (Noda
et al., 2006). Taken together, the data indicate that VP40 may
be transported within cells via the COPII transport system, which
is dependent on microtubules.
A reduction in VLP production with FLAG-VP40_M305A show-
ing an increased level of interaction with Sec24C provided
valuable insight into the processes underlying VP40 intracellular
transport and its involvement in virus budding. This finding sug-
gests that VP40 transport to the plasma membrane is initiated via
the COPII transport system through interaction with Sec24C and
then dissociates from the COPII complex, followed by interac-
tion with proteins associated with ESCRT complexes, such as
Tsg101 and Nedd4, to initiate virus budding. Thus, a strong
association of VP40 with Sec24C likely inhibits the proper transi-
tion of VP40 to other host machineries for the next steps in virus
budding. Whether VP40 interacts with cellular proteins within
ESCRT complexes, such as Tsg101 and Nedd4, immediately af-
ter dissociation from the COPII complex or whether other host
mechanisms are involved remains unknown. A full understand-
ing of Ebola virus budding will require studies to clarify how
VP40 proceeds to function at the viral budding site.
Unlike the VP40 of Ebola and Marburg viruses, the matrix
proteins of HIV-1 gag and Lassa virus Z do not appear to use
the COPII transport system. The latter proteins differ from the
former in that they are myristoylated, an essential modification
for their membrane association and virus budding (Gottlinger
et al., 1989; Perez et al., 2004). Thus, myristoylated proteins
may use a different intracellular transport pathway than the
one selected by VP40.
Three multiple alanine scanning mutants, FLAG-VP40_286-
288A, FLAG-VP40_289-291A, and FLAG-VP40_314-316A, inter-
acted with Sec24C in a manner similar to that of the wild-type
VP40, but showed reduced VLP production and reduced accu-
mulation at the plasma membrane. This result can be explained
in at least two ways. First, unknown host factors may fail to inter-
act with these mutant VP40s. In fact, the region spanning amino
acids 286–291 has been reported to be a part of a Crk SH3-bind-
ing site, composed of proline-rich, hydrophobic amino acids
(Aman et al., 2003). Although this region is not exposed on the
surface of VP40 molecule base on the three-dimensional struc-
ture analysis (Dessen et al., 2000), it could still be transiently
exposed. Second, amino acid changes at these positions may
have altered the conformation of VP40. Further studies willChelp to clarify whether Crk or its related proteins are involved in
VP40 intracellular transport.
In summary, our data suggest that Ebola VP40 relies on the
COPII transport system via interaction with Sec24C for its
intracellular transport. This system is responsible for vesicular
transport from the ER to the Golgi and is not thought to be
involved in cargo transport to the plasma membrane. Thus, it
will be important to clarify how the COPII complex transports
VP40 to the cell surface and how VP40 dissociation from the
complex is triggered. This information would greatly enhance
our understanding of the Ebola virus life cycle and may thus
provide a useful platform on which to develop novel strategies
to combat Ebola virus infections.
EXPERIMENTAL PROCEDURES
Cells
Human embryonic kidney cells (293 cells and 293T cells) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS) and a penicillin-streptomycin solution (SIGMA). shSec24C
293 cells, shSar1 293 cells, and shGFP 293 cells were maintained in
DMEM with 10% FCS and a penicillin-streptomycin solution and puromycin
(1 mg/ml). These cells were grown in an incubator at 37C under 5% CO2.
A Tandem-Tag-Based Pull-Down Assay
A tandem-tag-based pull-down assay was performed as previously reported
(Nakatani and Ogryzko, 2003) with some modifications. Briefly, 293T cells
transfected with plasmids expressing FH-VP40 or VP40 were collected at
24 hr posttransfection, lysed in lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 1 mM EDTA, 0.5% Nonidet P-40, and protease inhibitor cocktail
complete mini [Roche]), and incubated for 1 hr at 4C. After clarification by
low-speed centrifugation, the supernatants were incubated with anti-FLAG
M2 Affinity Gel (SIGMA) overnight at 4C. The FLAG-agarose beads were
then washed three times with lysis buffer and the binding proteins eluted
with FLAG elution buffer (50 mM Tris-HCl, 150 mM NaCl, and 0.5 mg/ml
FLAG peptide [SIGMA]) for 1 hr at 4C. After the FLAG-agarose beads were
removed by centrifugation, the supernatants were incubated with anti-HA
agarose conjugate clone HA-7 (SIGMA) overnight at 4C, and then eluted
with HA elution buffer (50 mM Tris-HCl, 1 M NaCl, and 0.5 mg/ml HA peptide
[SIGMA]) for 6 hr at 4C. The final eluted mixtures were then removed from the
HA-agarose beads, dialyzed with 50 mM Tris-HCl (pH = 7.5) for 6 hr at 4C, and
freeze dried. The dried protein mixtures were suspended in sample buffer
(Invitrogen), incubated for 10 min at 95C, and then subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed
by MALDI-TOF-TOF/MS system analysis (4700 Proteomics Analyzer, Applied
Biosystems) for identification of coimmunoprecipitated host proteins.
Immunoprecipitation Assay
293T cells cotransfected with plasmids expressing various FLAG-tagged pro-
teins and cMyc-tagged or authentic Sec24C or 293 cells infected with Ebola
virus were lysed in lysis buffer and maintained for 1 hr at 4C. After clarification
by centrifugation, the supernatants were incubated with anti-FLAG M2 Affinity
Gel, or anti-VP40 antibody, followed by protein G sepharose (GE Healthcare),
overnight at 4C. A fraction of the supernatant was then mixed with tricine
sample buffer (Invitrogen) and incubated for 10 min at 95C. The beads were
then washed three times with lysis buffer, suspended in tricine sample buffer,
and incubated for 10 min at 95C. After the FLAG beads were removed by cen-
trifugation, the samples were subjected to SDS-PAGE, followed either by
western blot analysis with a rabbit anti-cMyc antibody (SIGMA), a rabbit
anti-FLAG antibody (SIGMA), a rabbit anti-Sec24C antibody (kindly provided
by Dr. J.P. Paccaud, University of Basel) (Pagano et al., 1999), a rabbit anti-
Sec23 antibody (Affinity BioReagents), a rabbit anti-NP antibody (Noda
et al., 2006), a mouse anti-GP antibody (Watanabe et al., 2004), an anti-
VP24 antibody (Watanabe et al., 2007), or a rabbit anti-VP40 antibody (Noda
et al., 2006), or by CBB staining with SimplyBlue SafeStain (Invitrogen).ell Host & Microbe 3, 168–177, March 2008 ª2008 Elsevier Inc. 175
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Confluent 293 cells were infected with Zaire Ebola virus (Neumann et al., 2005)
at an moi of 1. After 1 hr at 37C, the inoculum was removed, and the cells were
washed with DMEM. Infected cells were maintained in DMEM supplement with
2% FCS for 3 days and then used for immunoprecipitation assays with an
anti-VP40 antibody. All work with infectious Ebola virus was performed in
the biosafety level 4 laboratories at the National Microbiology Laboratory of
the Public Health Agency of Canada in Winnipeg, Manitoba.
VLP Release Assay
At 24 or 48 hr posttransfection of the cells with plasmids expressing virus
matrix proteins in the presence or absence of FLAG-Sar1, FLAG-Sar1_T39N,
or FLAG-Sar1_H79G, the culture media were harvested and cleared of cell
debris. The cleared supernatants were then layered onto a 20% sucrose cush-
ion and ultracentrifuged in an SW55 rotor (Beckman) at 50,000 rpm for 2 hr at
4C. The pellet containing VLP was suspended in PBS and mixed with tricine
sample buffer. The VLP samples were then incubated at 95C for 10 min before
being resolved on 10%–20% tricine gels (Invitrogen). The plasmid-transfected
cells were also suspended in PBS, mixed with tricine sample buffer, and
resolved on 10%–20% tricine gels. Resolved proteins were detected with
a rabbit anti-VP40 antibody, a mouse anti-FLAG antibody, a mouse anti-p24
antibody (Advanced Biotechnologies Inc.), or a mouse anti-cMyc antibody
(SIGMA) by western blot analysis.
Immunofluorescence Assay
293 cells were transfected with plasmids expressing FLAG-tagged alanine
scanning mutants of VP40 or VP40, cMyc-Sec24C, and FLAG-Sec23A. After
24 hr, the cells were fixed with 4% paraformaldehyde and permeabilized
with 0.2% Triton X-100. Antigens were detected with a rabbit anti-VP40 or
a rabbit anti-cMyc antibody and a mouse anti-FLAG antibody, as the primary
antibody, followed by Alexa Fluor 488 goat anti-mouse IgG (Invitrogen) and
Alexa Fluor 594 goat anti-rabbit IgG (Invitrogen). In some experiments, nuclei
were stained with 40, 60-diamidino-2-phenylindole (DAPI) (Invitrogen). Slides
were imaged by confocal microscopy using an LSM510 system (Carl Zeiss).
Living Cell Imaging
293T cells were cotransfected with plasmids expressing Venus-VP40 and
FLAG-Sar1, FLAG-Sar1_T39N, or FLAG-Sar1_H79G. After 24 hr, the cells
were stained with 1 mM ER-tracker Blue-White (Molecular Probes) and imaged
with an LSM510 confocal microscope.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures and
eight supplemental figures and can be found with this article online at http://
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